Inventors: Arti Dhar

The study focuses on developing and characterizing inhibitors targeting the polymerase zeta subunit MAD2B/Rev7 as potential anticancer therapeutic agents. Polymerase zeta, involved in DNA damage tolerance, is a key player in cancer cell resistance to treatment. The research involves designing small molecules or compounds that specifically inhibit MAD2B/Rev7, and evaluating their efficacy through in-vitro (laboratory) and in-vivo (animal) models. By targeting this subunit, the study aims to disrupt cancer cell repair mechanisms, enhance the effectiveness of existing therapies, and offer new treatment options for various cancers. (Pharmacy)